Resources for You
Rapamune (sirolimus) tablets and oral solution
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – January 2010
- Hematological/Lymphatic – The concomitant use of Rapamune with a calcineurin inhibitor may increase the risk of calcineurin inhibitor induced HUS/TTP/TMA; pancytopenia, neutropenia
PATIENT COUNSELING INFORMATION
Skin Cancer Events
- Patients should be told that exposure to sunlight and ultraviolet (UV) light should be limited by wearing protective clothing and using a sunscreen with a high protection factor because of the increased risk for skin cancer.